Brensocatib, marketed as Brinsupri, has received FDA approval for the treatment of bronchiectasis, marking a significant advancement in the management of this condition. In...
The U.S. Food and Drug Administration (FDA) granted approval for brensocatib, marketed as Brinsupri, in August 2025. This marks a significant milestone as it...